These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9893620)

  • 1. Camptothecins: a review of their development and schedules of administration.
    O'Leary J; Muggia FM
    Eur J Cancer; 1998 Sep; 34(10):1500-8. PubMed ID: 9893620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer.
    Mollica A; Stefanucci A; Feliciani F; Cacciatore I; Cornacchia C; Pinnen F
    Curr Drug Deliv; 2012 Mar; 9(2):122-31. PubMed ID: 22283650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedule-dependent efficacy of camptothecins in models of human cancer.
    Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA
    Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512
    [No Abstract]   [Full Text] [Related]  

  • 8. Current perspectives on camptothecins in cancer treatment.
    Dancey J; Eisenhauer EA
    Br J Cancer; 1996 Aug; 74(3):327-38. PubMed ID: 8695345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of camptothecins.
    Iyer L; Ratain MJ
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S31-43. PubMed ID: 9750027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long story of camptothecin: From traditional medicine to drugs.
    Martino E; Della Volpe S; Terribile E; Benetti E; Sakaj M; Centamore A; Sala A; Collina S
    Bioorg Med Chem Lett; 2017 Feb; 27(4):701-707. PubMed ID: 28073672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camptothecins: a review of their chemotherapeutic potential.
    Ulukan H; Swaan PW
    Drugs; 2002; 62(14):2039-57. PubMed ID: 12269849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
    Danks MK; Pawlik CA; Whipple DO; Wolverton JS
    Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
    Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
    Vassal G; Pondarré C; Boland I; Cappelli C; Santos A; Thomas C; Lucchi E; Imadalou K; Pein F; Morizet J; Gouyette A
    Biochimie; 1998 Mar; 80(3):271-80. PubMed ID: 9615866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical applications of the camptothecins.
    Takimoto CH; Wright J; Arbuck SG
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
    Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
    Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
    Hartmann JT; Lipp HP
    Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.